Pharmaceutical Technology

SEPTEMBER 30, 2022

Spark Therapeutics’ Luxturna, indicated for inherited retinal disease (IRD), was the first gene therapy to be approved, in 2017, with a price tag of $850,000 for each eye. bluebird then broke its own pricing record when the $3m Skysona was approved, and now faces the unique challenge of selling the world's two most expensive drugs.

FDA 115

FDA Insurance Patients Marketing 115

pharmaphorum

JANUARY 9, 2023

Novartis’ programme providing free access to its spinal muscular atrophy (SMA) gene therapy Zolgensma is being scaled back to a dozen countries worldwide, according to the company. ” Zolgensma is one of the most expensive therapies available, with a price tag of around $2.1

Side effects 106

Side effects Patients Management Marketing 106

European Pharmaceutical Review

MAY 11, 2023

Novartis shared long-term data for its SMA gene therapy in March 2023, which indicated significant long-term motor-milestone achievements in spinal muscular atrophy (SMA). What were the main findings presented at the 2023 Muscular Dystrophy Association Conference (MDA)? Available from: [link] Spinal Muscular Atrophy.

Food and Drug Administration 72

Food and Drug Administration Government Healthcare Healthcare 72

pharmaphorum

NOVEMBER 16, 2022

However, with a price tag of €1.58 million dollars for the one-time treatment, which is used to treat children less than two years old with spinal muscular atrophy, it is listed far higher than ICER’s recommendation of between $310,000-$900,000 per treatment. How to navigate the new climate. At more than $2.1

Medicine 117

Medicine Marketing Healthcare Healthcare 117